AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT108.33-0.46 (-0.42%) ▼|ACN186.72-6.40 (-3.31%) ▼|ADBE266.51-19.24 (-6.73%) ▼|AMAT454.71+18.80 (+4.31%) ▲|AMD477.57+21.41 (+4.69%) ▲|AMGN437.23-6.89 (-1.55%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN258.51-0.39 (-0.15%) ▼|AVGO357.90+0.74 (+0.21%) ▲|AXP326.16-3.66 (-1.11%) ▼|BA212.25+1.74 (+0.83%) ▲|BAC62.68-0.04 (-0.06%) ▼|BKNG193.29-1.84 (-0.94%) ▼|BLK1,122.29-3.86 (-0.34%) ▼|BMY66.82-1.27 (-1.87%) ▼|BNY164.84+0.51 (+0.31%) ▲|BRK-B506.03-2.10 (-0.41%) ▼|C137.72-0.42 (-0.30%) ▼|CAT813.94+13.80 (+1.72%) ▲|CL88.77-1.32 (-1.47%) ▼|CMCSA26.49-0.16 (-0.60%) ▼|COF219.60-0.90 (-0.41%) ▼|COP134.26-1.46 (-1.08%) ▼|COST915.74-9.67 (-1.04%) ▼|CRM259.23-5.20 (-1.97%) ▼|CSCO109.20+0.59 (+0.54%) ▲|CVS96.74-0.46 (-0.47%) ▼|CVX208.60-2.72 (-1.29%) ▼|DE693.53-0.88 (-0.13%) ▼|DHR207.66-3.37 (-1.60%) ▼|DIS105.31-1.85 (-1.73%) ▼|DUK120.22-1.18 (-0.97%) ▼|EMR152.82+2.61 (+1.74%) ▲|FDX322.52-1.79 (-0.55%) ▼|GD359.39-6.48 (-1.77%) ▼|GE337.12+3.64 (+1.09%) ▲|GEV941.95+0.11 (+0.01%) ▲|GILD151.00-0.23 (-0.15%) ▼|GM87.76+0.72 (+0.83%) ▲|GOOG335.31-3.77 (-1.11%) ▼|GOOGL338.46-3.80 (-1.11%) ▼|GS1,038.61+0.68 (+0.07%) ▲|HD321.05+2.98 (+0.94%) ▲|HON209.61+1.98 (+0.95%) ▲|IBM234.89+0.18 (+0.08%) ▲|INTC95.80+4.13 (+4.51%) ▲|INTU332.70-11.60 (-3.37%) ▼|ISRG366.70-3.13 (-0.85%) ▼|JNJ275.23-3.20 (-1.15%) ▼|JPM358.64-3.42 (-0.94%) ▼|KO88.07-0.74 (-0.83%) ▼|LIN477.57-4.62 (-0.96%) ▼|LLY1,149.36-10.24 (-0.88%) ▼|LMT525.28-7.67 (-1.44%) ▼|LOW204.45+2.55 (+1.26%) ▲|LRCX307.65+14.99 (+5.12%) ▲|MA579.21-6.50 (-1.11%) ▼|MCD255.69-3.94 (-1.52%) ▼|MDLZ61.28-0.17 (-0.28%) ▼|MDT94.17+1.07 (+1.15%) ▲|META616.77+6.09 (+1.00%) ▲|MMM168.56+0.25 (+0.15%) ▲|MO68.88-0.61 (-0.88%) ▼|MRK150.33-2.01 (-1.32%) ▼|MS217.72+0.57 (+0.26%) ▲|MSFT499.70-10.42 (-2.04%) ▼|MU1,016.59+58.43 (+6.10%) ▲|NEE83.43-0.63 (-0.75%) ▼|NFLX78.25-4.42 (-5.35%) ▼|NKE38.40-0.37 (-0.95%) ▼|NOW141.26-4.33 (-2.97%) ▼|NVDA230.36+1.91 (+0.84%) ▲|ORCL158.78+4.74 (+3.08%) ▲|PEP137.63-0.91 (-0.66%) ▼|PFE28.45-0.36 (-1.25%) ▼|PG146.44-0.48 (-0.33%) ▼|PLTR174.33-8.20 (-4.49%) ▼|PM182.53-3.64 (-1.96%) ▼|QCOM168.74+0.17 (+0.10%) ▲|RTX200.79-1.34 (-0.66%) ▼|SBUX104.47-1.35 (-1.28%) ▼|SCHW109.29-1.09 (-0.99%) ▼|SO88.11-0.66 (-0.74%) ▼|SPG209.44-2.08 (-0.98%) ▼|T25.68-0.51 (-1.95%) ▼|TMO613.78-4.65 (-0.75%) ▼|TMUS181.52-6.50 (-3.46%) ▼|TSLA354.08-22.29 (-5.92%) ▼|TXN258.44+4.61 (+1.82%) ▲|UBER75.76-0.20 (-0.26%) ▼|UNH397.14-3.80 (-0.95%) ▼|UNP289.62+0.47 (+0.16%) ▲|UPS102.29-1.21 (-1.17%) ▼|USB63.37-0.16 (-0.25%) ▼|V375.07-3.68 (-0.97%) ▼|VZ50.14-0.45 (-0.89%) ▼|WFC89.97+0.78 (+0.87%) ▲|WMT107.14-1.28 (-1.18%) ▼|XOM159.47-2.74 (-1.69%) ▼|AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT108.33-0.46 (-0.42%) ▼|ACN186.72-6.40 (-3.31%) ▼|ADBE266.51-19.24 (-6.73%) ▼|AMAT454.71+18.80 (+4.31%) ▲|AMD477.57+21.41 (+4.69%) ▲|AMGN437.23-6.89 (-1.55%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN258.51-0.39 (-0.15%) ▼|AVGO357.90+0.74 (+0.21%) ▲|AXP326.16-3.66 (-1.11%) ▼|BA212.25+1.74 (+0.83%) ▲|BAC62.68-0.04 (-0.06%) ▼|BKNG193.29-1.84 (-0.94%) ▼|BLK1,122.29-3.86 (-0.34%) ▼|BMY66.82-1.27 (-1.87%) ▼|BNY164.84+0.51 (+0.31%) ▲|BRK-B506.03-2.10 (-0.41%) ▼|C137.72-0.42 (-0.30%) ▼|CAT813.94+13.80 (+1.72%) ▲|CL88.77-1.32 (-1.47%) ▼|CMCSA26.49-0.16 (-0.60%) ▼|COF219.60-0.90 (-0.41%) ▼|COP134.26-1.46 (-1.08%) ▼|COST915.74-9.67 (-1.04%) ▼|CRM259.23-5.20 (-1.97%) ▼|CSCO109.20+0.59 (+0.54%) ▲|CVS96.74-0.46 (-0.47%) ▼|CVX208.60-2.72 (-1.29%) ▼|DE693.53-0.88 (-0.13%) ▼|DHR207.66-3.37 (-1.60%) ▼|DIS105.31-1.85 (-1.73%) ▼|DUK120.22-1.18 (-0.97%) ▼|EMR152.82+2.61 (+1.74%) ▲|FDX322.52-1.79 (-0.55%) ▼|GD359.39-6.48 (-1.77%) ▼|GE337.12+3.64 (+1.09%) ▲|GEV941.95+0.11 (+0.01%) ▲|GILD151.00-0.23 (-0.15%) ▼|GM87.76+0.72 (+0.83%) ▲|GOOG335.31-3.77 (-1.11%) ▼|GOOGL338.46-3.80 (-1.11%) ▼|GS1,038.61+0.68 (+0.07%) ▲|HD321.05+2.98 (+0.94%) ▲|HON209.61+1.98 (+0.95%) ▲|IBM234.89+0.18 (+0.08%) ▲|INTC95.80+4.13 (+4.51%) ▲|INTU332.70-11.60 (-3.37%) ▼|ISRG366.70-3.13 (-0.85%) ▼|JNJ275.23-3.20 (-1.15%) ▼|JPM358.64-3.42 (-0.94%) ▼|KO88.07-0.74 (-0.83%) ▼|LIN477.57-4.62 (-0.96%) ▼|LLY1,149.36-10.24 (-0.88%) ▼|LMT525.28-7.67 (-1.44%) ▼|LOW204.45+2.55 (+1.26%) ▲|LRCX307.65+14.99 (+5.12%) ▲|MA579.21-6.50 (-1.11%) ▼|MCD255.69-3.94 (-1.52%) ▼|MDLZ61.28-0.17 (-0.28%) ▼|MDT94.17+1.07 (+1.15%) ▲|META616.77+6.09 (+1.00%) ▲|MMM168.56+0.25 (+0.15%) ▲|MO68.88-0.61 (-0.88%) ▼|MRK150.33-2.01 (-1.32%) ▼|MS217.72+0.57 (+0.26%) ▲|MSFT499.70-10.42 (-2.04%) ▼|MU1,016.59+58.43 (+6.10%) ▲|NEE83.43-0.63 (-0.75%) ▼|NFLX78.25-4.42 (-5.35%) ▼|NKE38.40-0.37 (-0.95%) ▼|NOW141.26-4.33 (-2.97%) ▼|NVDA230.36+1.91 (+0.84%) ▲|ORCL158.78+4.74 (+3.08%) ▲|PEP137.63-0.91 (-0.66%) ▼|PFE28.45-0.36 (-1.25%) ▼|PG146.44-0.48 (-0.33%) ▼|PLTR174.33-8.20 (-4.49%) ▼|PM182.53-3.64 (-1.96%) ▼|QCOM168.74+0.17 (+0.10%) ▲|RTX200.79-1.34 (-0.66%) ▼|SBUX104.47-1.35 (-1.28%) ▼|SCHW109.29-1.09 (-0.99%) ▼|SO88.11-0.66 (-0.74%) ▼|SPG209.44-2.08 (-0.98%) ▼|T25.68-0.51 (-1.95%) ▼|TMO613.78-4.65 (-0.75%) ▼|TMUS181.52-6.50 (-3.46%) ▼|TSLA354.08-22.29 (-5.92%) ▼|TXN258.44+4.61 (+1.82%) ▲|UBER75.76-0.20 (-0.26%) ▼|UNH397.14-3.80 (-0.95%) ▼|UNP289.62+0.47 (+0.16%) ▲|UPS102.29-1.21 (-1.17%) ▼|USB63.37-0.16 (-0.25%) ▼|V375.07-3.68 (-0.97%) ▼|VZ50.14-0.45 (-0.89%) ▼|WFC89.97+0.78 (+0.87%) ▲|WMT107.14-1.28 (-1.18%) ▼|XOM159.47-2.74 (-1.69%) ▼|
22 C
New York
Saturday, September 5, 2026

Tag: drug

newssourceFORcompanyinformationcontent1releasesmarket

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

Abivax Announces Launch of Public Offering

Abivax Announces Launch of Public Offering

British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)

TORONTO, July 23, 2025 /CNW/ - Elvium Life Sciences is pleased to announce the addition of FOQUEST® (methylphenidate hydrochloride controlled release capsules) to the British...

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid...

Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for...

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

- XIPERE Now Approved for Use in Multiple Global Markets -

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug...

Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons

BEACHWOOD, Ohio, July 23, 2025 /PRNewswire/ -- Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells...

Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening

Compounds developed through collaboration with Variational AI show targeted activity 
Compounds developed through collaboration with Variational AI show targeted activity

Samsung Biologics reports second quarter 2025 financial results

Recorded Q2'25 consolidated revenue of KRW 1,289.9 billionRecorded Q2'25 consolidated operating profit of KRW 475.6 billionSolid momentum sustained through capacity ramp-up and stable project...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 5, 2025 to report its second quarter 2025 financial results and provide a corporate update.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers